The most commonly reported adverse effects in the Phase 2 trial included: Nausea the most prevalent side effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst contributing to weight loss, can be uncomfortable) Eructation (belching) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects are typically mild to moderate in severity and tend to be most pronounced during the first few weeks of treatment or following each dose increase
Hua, H., et al., Reduction of NADPH oxidase 4 in adipocytes contributes to the anti-obesity effect of dihydroartemisinin
Along with a Whey protein Isolate in the early morning after waking I have gained control of my high level of stress, poor sleep, and erratic hunger cues
Metformin, if not contraindicated, is the preferred first line pharmacological agent for type 2 diabetes 14
It functions as a triple receptor agonist at the GIP, GLP-1, and glucagon receptors
Unraveling adipose tissue dysfunction: molecular Mechanisms, novel Biomarkers, and therapeutic targets for liver fat deposition